Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 19/20 | 0.58 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.58 |
| ▸ | CDK2 | P24941 | 5/20 | 0.58 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.58 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14542956 | 0.87 | CHEK1 (0.78) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL11931272 | 0.86 | CHEK1 (0.77) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL14231706 | 0.84 | CHEK1 (0.78) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL11931613 | 0.79 | KDM4E (0.49) | CHEK1CCNA2CDK2CCNA1TYRO3 | |
| SCHEMBL11931358 | 0.79 | IRAK1 (0.47) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL13305063 | 0.78 | PSD (0.40) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL13304791 | 0.76 | GSK3B (0.39) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL12953240 | 0.76 | GSK3B (0.55) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL13304840 | 0.75 | GSK3B (0.38) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL12953531 | 0.75 | CHEK1 (0.55) | CHEK1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070082900-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082900-A1 | Methods for inhibiting protein kinases | PIM1, AURKC, PIM3 | CHEK1 8/4885CCNA2 1270/4885CDK2 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.